Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BLSM by emailGet an email when BLSM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BLSM, unsubscribe in one click. Privacy
📣 What BLSM Says Is Next
Q1 2027 · “BlossomHill plans to initiate a global Phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.”
Company press release, Sep 15, 2026 · SEC filing
in 2027 · “Together with the recent FDA Fast Track designation, these data strengthen our conviction in the potential of BH-30643 and support our plans to advance into a Phase 2 trial in patients with C797S-positive NSCLC in 2027.” Presentation highlights: As of the May 12, 2026 data cutoff, with efficacy follow-up through August 10, 2026:”
Company press release, Sep 15, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BLSM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BLSM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.